FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Private Issuer
Pursuant to Rule 13s - 16 or 15d - 16 of
the Securities Exchange Act of 1934
For the month of September 2005
Acambis plc
(Translation of registrant's name into English)
Peterhouse Technology Park
100 Fulbourn Road
Cambridge CB1 9PT
England
(address of principal executive offices)
(Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F
Forms 20-F X Form 40-F
Indicate by check mark whether the registrant by furnishing the information
contained in this Form also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934).
Yes No X
(if "Yes" is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): 82- ).
Enclosure: 1. Holding(s) in Company released on 01 September 2005
2. Holding(s) in Company released on 13 September 2005
3. Director/PDMR Shareholding released on 14 September 2005
4. Re Contract released on 19 September 2005
5. Holding(s) in Company released on 27 September 2005
Enclosure No.1
Holding in Company
Cambridge, UK and Cambridge, Massachusetts - 1 September 2005 - Acambis plc
("Acambis") (LSE: ACM, NASDAQ: ACAM) announces an interest in its shares by The
Goldman Sachs Group, Inc.
On 31 August 2005, Acambis received notification that, as of the close of
business on 25 August 2005, following a purchase of shares, The Goldman Sachs
Group, Inc., ("GS Inc") of 85 Broad Street, New York, NY 10004, USA, was
interested in a total of 3,248,396 ordinary shares of 10p each, representing a
3.03% holding of Acambis' issued share capital.
Of these 3,248,396 shares:
a) the interest in 261,165 shares arose from an interest held
by Goldman, Sachs & Co. ("GS&Co."), a direct subsidiary of GS Inc, acting as
custodian; these shares are, or will be, registered in the name of Goldman Sachs
Securities (Nominees), Limited ("GSSN");
b) the interest in 1,136,200 shares arose from an interest
held by a direct subsidiary of GS&Co, acting as custodian of 568,100 American
Depositary Receipts ("ADRs"); these ADRs are, or will be, held at The Depositary
Trust Company, New York;
c) the interest in 47,630 shares arose from the interest held
by GS&Co. a direct subsidiary of GS Inc, acting as discretionary manager. These
shares are, or will be, registered in the name of GSSN; and
d) the interest in 1,803,401 shares arose from a beneficial
interest held by Goldman Sachs International, a direct subsidiary of GS Inc;
these shares are, or will be, registered at CREST in account CREPTEMP.
-ends-
Enquiries:
Acambis plc
Elizabeth Brown, Company Secretary: Tel: +44 (0) 1223 275 300
Lyndsay Wright, VP, Communications and Investor Relations: Tel: +44 (0) 1223 275
300
About Acambis
Acambis is a leading developer of vaccines to prevent and treat infectious
diseases. Recognised internationally as the leading producer of smallpox
vaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000,
and is manufacturing emergency-use stockpiles of this investigational vaccine
for the US Government and other governments around the world. It is also
developing an attenuated smallpox vaccine, MVA3000, under contracts with the US
National Institutes of Health. Acambis is establishing a travel vaccines
franchise through its US-based subsidiary Berna Products Corporation, which
markets Vivotif(R), the world's only licensed oral typhoid vaccine, in North
America. Acambis has other potential travel vaccines in development and is also
developing an investigational vaccine against the West Nile virus, which has
spread to 48 US States in the last six years.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US. Its primary
listing is on the London Stock Exchange (ACM) and its shares are listed in the
form of American Depositary Receipts on NASDAQ (ACAM). More information is
available at www.acambis.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2004 Annual Report and "Risk factors" in the 2004 Form 20-F, in
addition to those detailed on the Company's website and in the Company's filings
made with the Securities and Exchange Commission from time to time. These
forward-looking statements are based on estimates and assumptions made by the
management of Acambis and are believed to be reasonable, though are inherently
uncertain and difficult to predict. Actual results or experience could differ
materially from the forward-looking statements.
Enclosure No.2
SCHEDULE 10
NOTIFICATION OF MAJOR INTERESTS IN SHARES
1. Name of company
Acambis plc
2. Name of shareholder having a major interest
Morley Fund Management Limited (a subsidiary of Aviva plc)
3. Please state whether notification indicates that it is in respect of holding
of the shareholder named in 2 above or in respect of a non-beneficial interest
or in the case of an individual holder if it is a holding of that person's
spouse or children under the age of 18
As above
4. Name of the registered holder(s) and, if more than one holder, the number of
shares held by each of them
BNY Norwich Union Nominees Ltd 984,973 shares
Chase GA Group Nominees Ltd 1,994,834 shares
Chase Nominees Ltd 267,679 shares
CUIM Nominee Ltd 959,670 shares
5. Number of shares / amount of stock acquired
N/A
6. Percentage of issued class
N/A
7. Number of shares transferred out of the holding
100,000 shares
8. Percentage of issued class
0.09%
9. Class of security
Ordinary shares of 10p each
10. Date of transaction
9 September 2005
11. Date company informed
12 September 2005
12. Total holding following this notification
4,207,156 shares
13. Total percentage holding of issued class following this notification
3.92%
14. Any additional information
N/A
15. Name of contact and telephone number for queries
Elizabeth Brown, Company Secretary
+44 (0) 1223 275 300
16. Name and signature of authorised company official responsible for making
this notification
Elizabeth Brown
Date of notification
13 September 2005
The FSA does not give any express or implied warranty as to the accuracy of this
document or material and does not accept any liability for error or omission.
The FSA is not liable for any damages (including, without limitation, damages
for loss of business or loss of profits) arising in contract, tort or otherwise
from the use of or inability to use this document, or any material contained in
it, or from any action or decision taken as a result of using this document or
any such material.
Enclosure No.3
Directors' interests in shares
Cambridge, UK and Cambridge, Massachusetts - 14 September 2005 - Acambis plc
("Acambis") (LSE: ACM, NASDAQ: ACAM) announces that, on 13 September 2005, the
following grants of options under the Acambis 1999 Share Option Scheme were made
to the three Executive Directors:
Total shares over which
Director Share options options held (note 1)
Gordon Cameron 68,525 726,331
David Lawrence 37,350 293,979
Dr Thomas Monath 35,995 443,579
The share options were granted over ordinary 10p shares at an exercise price of
251p per share. The exercise periods applicable are 13 September 2008 to 12
September 2015. No amount was payable by the Directors on the grant of these
share options.
Note 1: The total shares over which options are held (share options and
long-term incentive awards) following the above transactions detailed within
this news release.
Enquiries:
Acambis plc
Elizabeth Brown, Company Secretary Tel: +44 (0) 1223 275 300
Lyndsay Wright, VP, Communications and Investor
Relations
-ends-
About Acambis
Acambis is a leading developer of vaccines to prevent and treat infectious
diseases. Recognised internationally as the leading producer of smallpox
vaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000,
and is manufacturing emergency-use stockpiles of this investigational vaccine
for the US Government and other governments around the world. It is also
developing an attenuated smallpox vaccine, MVA3000, under contracts with the US
National Institutes of Health. Acambis is establishing a travel vaccines
franchise through its US-based subsidiary Berna Products Corporation, which
markets Vivotif(R), the world's only licensed oral typhoid vaccine, in North
America. Acambis has other potential travel vaccines in development and is also
developing an investigational vaccine against the West Nile virus, which has
spread to 48 US States in the last six years.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US. Its primary
listing is on the London Stock Exchange (ACM) and its shares are listed in the
form of American Depositary Receipts on NASDAQ (ACAM). More information is
available at www.acambis.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2004 Annual Report and "Risk factors" in its Form 20-F, in
addition to those detailed on the Company's website and in the Company's filings
made with the Securities and Exchange Commission from time to time. These
forward-looking statements are based on estimates and assumptions made by the
management of Acambis and are believed to be reasonable, though are inherently
uncertain and difficult to predict. Actual results or experience could differ
materially from the forward-looking statements.
Enclosure No.4
Acambis helps Cangene win C-VIG supply contract from UK Department of Health
Cambridge, UK and Cambridge, Massachusetts - 19 September 2005 - Acambis plc ("
Acambis") (LSE: ACM, NASDAQ: ACAM) announces the award of a contract to Cangene
Corporation ("Cangene") (TSX: CNJ) for the supply of its Vaccinia Immune
Globulin Intravenous (Human) ("VIG") product to the UK Department of Health ("
DoH"). Acambis is the sales agent to Cangene for VIG in territories outside
North America and Israel and was instrumental in securing the contract with the
DoH.
The contract was awarded to Cangene by the UK Government and full delivery is
expected by 31 July 2006.
VIG, approved by the US Food and Drug Administration ("FDA") in May 2005, is a
treatment for some of the potential, serious adverse reactions that may result
from smallpox vaccination.
Acambis, in conjunction with its distribution partner Baxter Healthcare SA and
on behalf of Cangene, is currently in discussions with a number of other
governments for the supply of VIG.
Gordon Cameron, Chief Executive Officer of Acambis, said:
"Acambis is delighted to be involved in the award to Cangene of a contract for
the supply of VIG to the UK Department of Health. VIG is an important
complementary product to smallpox vaccine stockpiles as part of governments'
preparedness strategies against a potential bioterrorist attack."
-ends-
Enquiries:
Acambis plc
Gordon Cameron, Chief Executive Officer: Tel +44 (0) 1223 275 300
David Lawrence, Chief Financial Officer: Tel +44 (0) 1223 275 300
Lyndsay Wright, VP, Communications and Investor Relations:
Tel +44 (0) 1223 275 300
Financial Dynamics
David Yates/Davina Langdale: Tel +44 (0) 20 7831 3113
About Acambis
Acambis is a leading developer of vaccines to prevent and treat infectious
diseases. Recognised internationally as the leading producer of smallpox
vaccines, Acambis is developing an investigational smallpox vaccine, ACAM2000,
and is manufacturing emergency-use stockpiles of this investigational vaccine
for the US Government and other governments around the world. It is also
developing an attenuated smallpox vaccine, MVA3000, under contracts with the US
National Institutes of Health. Acambis is establishing a travel vaccines
franchise through its US-based subsidiary Berna Products Corporation, which
markets Vivotif(R), the world's only licensed oral typhoid vaccine, in North
America. Acambis has other potential travel vaccines in development and is also
developing an investigational vaccine against the West Nile virus, which has
spread to 48 US States in the last six years.
Acambis is based in Cambridge, UK and Cambridge, Massachusetts, US. Its primary
listing is on the London Stock Exchange (ACM) and its shares are listed in the
form of American Depositary Receipts on NASDAQ (ACAM). More information is
available at www.acambis.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of
1995:
The statements in this news release that are not historical facts are
forward-looking statements that involve risks and uncertainties, including the
timing and results of clinical trials, product development, manufacturing and
commercialisation risks, the risks of satisfying the regulatory approval process
in a timely manner, the need for and the availability of additional capital. For
a discussion of these and other risks and uncertainties see "Risk management" in
the Company's 2004 Annual Report and "Risk factors" in its Form 20-F, in
addition to those detailed on the Company's website and in the Company's filings
made with the Securities and Exchange Commission from time to time. These
forward-looking statements are based on estimates and assumptions made by the
management of Acambis and are believed to be reasonable, though are inherently
uncertain and difficult to predict. Actual results or experience could differ
materially from the forward-looking statements.
Enclosure No.5
Acambis plc ("the Company")
DISCLOSURE OF INTEREST
The Company received notification on 26 September 2005 that, as of close of
business on 23 September 2005, Morley Fund Management Limited (a subsidiary of
Aviva plc) no longer held a disclosable interest in the ordinary shares of 10p
each in the Company.
-ends-
Enquiries:
Acambis plc
Elizabeth Brown, Company Secretary
Tel: +44 (0) 1223 275 300
27 September 2005
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant Peptide Therapeutics Group has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.
Date: 30 September 2005 ACAMBIS PLC
By: /s/ Lyndsay Wright
Name: Lyndsay Wright
Title: Director of Communications